SAN DIEGO, CA–(Marketwire – March 11, 2010) – Entest BioMedical, Inc. (OTCBB: ENTB) announced today its CEO David Koos addressed the Company’s shareholders and other interested parties on its new blog site. Topics covered in the interview included progress in the Stem Cell / Photoceutical treatment for COPD, immunotherapeutic cancer vaccine, potential grant funding and anticipated revenue sources for the Company. This interview may be heard on the Company’s blog site, www.entestbioblog.com/live.

Further information:

Article source

Related posts:

1. Entest BioMedical CEO to Address Shareholders on Entestbioblog.com/live
2. Entest BioMedical Strengthens Its Research Capabilities by Adding Clinical Trials Expert Dr. Vladimir Bogin to Its Scientific Advisory Board
3. William A. Hawkins, Medtronic Chairman And CEO, Receives Distinguished Achievement Award From Biomedical Engineering Society
4. Cancer Research UK And Immatics Biotechnologies To Trial Vaccine For Brain Cancer
5. Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President